State-of-the-art treatment of advanced-stage ovarian carcinoma includes radical cytoreductive surgery aiming at the removal of all visible tumour, followed by six cycles of platinum/paclitaxel (PT) chemotherapy. The completeness of surgical tumour removal is among the most powerful predictors of patient outcome (du Bois et al, 2003) . Currently, there are no additional generally accepted prognostic markers independent from the established clinical factors like International Federation of Gynaecology and Obstetrics (FIGO) stage, postoperative residual tumour, patient age and clinical performance status (Crawford et al, 2005) .
The retinoblastoma (RB) regulatory pathway of cell cycle control is deregulated in virtually all human tumour types (Cobrinik, 2005; Korenjak and Brehm, 2005; Macaluso et al, 2005) . In a physiological cell state, the ability of the retinoblastoma protein (pRb) to control cell cycle progression via binding members of the E2F transcription factor family is controlled by cyclin D/cdk4-mediated phosporylation. The p16
INK4a protein has been shown to inhibit the phosphorylating activity of this functional cyclin D/cdk4complex, thus abrogating the E2F-induced activation of genes important for driving the cell cycle into S-phase progression. Various specific genetic alterations of individual members of the pRB-regulated pathway, including cyclin D, cdk4 and cyclindependent kinase inhibitor p16
INK4a , contribute to the impairment of cell cycle control at the G1 S-phase transition in different tumour types. Deregulated expression of cell cycle promoting cyclins, often resulting from specific tumour-associated gene amplification, represents a common mechanism leading to loss of cell cycle control, as well as genetic loss or transcriptional downregulation of cellcycle inhibitory factors, for example pRb and the CDK inhibitor p16
INK4a (Pei and Xiong, 2005; Sharpless, 2005) . However, p16
INK4a expression has also been found to be strongly upregulated in certain neoplasms, such as cervical cancers and cervical high-grade dysplasias (Klaes et al, 2001) . In proliferating cells from these cervical precancerous and cancerous lesions, the E7 protein from high-risk human papillomaviruses (HPV) inactivates the pRb -E2F transcription factor complex, thus releasing the negative transcriptional control of the p16 INK4a gene mediated by functional pRb -E2F complex. Besides its potential utility as a diagnostic marker for the identification of cervical lesions, overexpression of p16
INK4a has been reported to represent a characteristic of mammary carcinomas associated with a poor prognosis (Milde-Langosch et al, 2001) . In ovarian cancer, expression of p16 INK4a and pRb has been investigated in various studies using immunohistochemistry (Dong et al, 1997a, b; Niemann et al, 1998; Kusume et al, 1999; Sui et al, 2000; Milde-Langosch et al, 2003; Raspollini et al, 2004; Hashiguchi et al, 2004) . However, the results from these studies provided conflicting information concerning the expression of pRb and p16
INK4a , and the prognostic significance of differential expression levels of these cellcycle regulatory proteins in ovarian carcinomas. Most of the previous studies are characterised by either a relatively low number of cases analysed, or by a broad heterogeneity with respect to stage and postoperative therapy, or by only limited follow-up data being available. Therefore, this study aimed to test the hypothesis that expression of cell-cycle regulatory proteins p16
INK4a and pRb is significantly associated with prognosis in a large, homogeneous series of advanced-stage ovarian carcinomas receiving standardised chemotherapy after radical surgery (du Bois et al, 2003) .
MATERIALS AND METHODS

Study material
After completion of a prospective randomised, multi-centre, phase III study of a total of 798 patients with ovarian cancer, FIGO-stages IIB -IV, comparing cisplatin 75 mg m À2 plus 185 mg m À2 PT with PT 185 mg m À2 plus carboplatin (TC) (du Bois et al, 2003) , tissue blocks were requested from participating centres for translational research. Between one and 53 paraffin blocks per case were received from a total of 334 study patients. An explorative comparison of patient characteristics between patients with or without available paraffin blocks was performed. Paraffin sections were cut from all blocks and stained with Haematoxylin and Eosin. After review of all slides and exclusion of material which contained no tumour tissues, or which was insufficient for adequate histopathological analysis (32 cases), between one and nine stained sections each from a total of 300 cases of primary invasive epithelial ovarian carcinomas were available for further studies. All slides were reviewed by two experienced gynaecopathologists (FK, DS) who were blinded for the outside diagnoses. All ovarian carcinomas were typed according to the current WHO criteria and classified as either serous, mucinous, endometrioid, clear cell, transitional cell or undifferentiated carcinoma (Scully, 1999; Tavassoli and Devilee, 2003) .
Immunohistochemistry
Sections 2 -4 mm were cut from paraffin blocks, deparaffinised in xylene and rehydrated. Antigen retrieval for p16
INK4a immunostaining was performed by incubating slides in 0.01 M citrate buffer (pH 6.0) for 40 min at 951C in a water bath (Pasha, Montone and Tomaszewski, 1995) , sections for pRb immunostaining in 0.1 M sodium citrate buffer (pH 6.0) for 20 min in a microwave oven (Shi, Key and Kalra, 1991) . For p16
INK4a immunostaining, mouse monoclonal antibody clone E6H4 (mtm laboratories, Heidelberg, Germany) was used. A polymer-horseradish peroxidase-based secondary reagent system (Envision þ , Dako A/S, Glostrup, Denmark) was used for signal generation following the instructions of the manufacturer. For pRb-immunostaining, mouse monoclonal antibody clone 3C8 (QED Bioscience Inc., San Diego, CA, USA) (Wen et al, 1994 ) was used at a 1:450 dilution. Signal generation was carried out following the VECTASTAIN s ELITE ABC KIT protocol (Vector Laboratories, Burlingame, CA, USA). 3,3 0 -Diaminobenzidine hydrochloride was used as chromogen for both immunostaining protocols, and slides were finally counterstained with Mayeŕs Hemalaun. Appropriate positive controls (for p16 INK4a : cervical high-grade lesions (CIN III), for pRb: breast cancer specimens) and negative reagent controls were included in each staining run. Proliferation activity was measured immunohistochemically using monoclonal Ki-S5 antibody (kindly provided by R Parwaresch, Institute of Pathology, University of Kiel, Germany) as described (Kreipe et al, 1993) .
Evaluation of immunostains p16
INK4a and pRb immunostaining intensities (ISI: no staining ¼ 0; weak staining ¼ 1; medium staining ¼ 2; strong staining ¼ 3) and percentages of positively stained cells (PPC: 0% ¼ 0; o10% ¼ 1; 10 -50% ¼ 2; 51 -80% ¼ 3; 480% ¼ 4) were assessed for each tumour. Negative and weak ISI were considered low pRb, mean and strong ISI were considered high pRb. Proliferative activity as measured by Ki-S5 immunostaining was calculated as percentage of positive cells. Any unequivocal nuclear staining of neoplastic epithelial tumour cells was considered specific.
For p16 INK4a evaluation, staining patterns of nuclear only, cytoplasmatic only and combined nuclear/cytoplasmatic were accepted as specific; for pRb any unequivocal nuclear staining of epithelial tumour cells was considered specific. For evaluation of Ki-S5 staining, the respective area showing the highest level of proliferation for each tumour specimen was identified at low 
Statistical analysis
The exploratory analysis of possible selection bias of the study population was performed by the w 2 -test (Armitage and Berry, 1994) . Survival analysis was performed according to the method of Kaplan and Meier (Kaplan and Meier, 1958) , survival times were compared using the log rank test (Mantel, 1966) applying SPSS13 software (SPSS for Windows, Rel. 13.0.1., 2004). Multivariate analyses were performed using the Cox regression (Cox, 1972) .
RESULTS
From a randomised prospective trial of patients receiving standardised postoperative chemotherapy after radical surgery, 300 cases of primary invasive epithelial ovarian carcinoma were selected without following any rule, other than being dependent on availability of material and willingness to cooperate. No significant selection bias was found after explorative analysis of patient characteristics (patient age, Eastern Cooperative Oncology Group (ECOG) clinical performance status, FIGO stage, preoperative extraovarian tumour, postoperative residual tumour) comparing patients with and without available paraffin blocks by w 2 -analysis (data not shown). The distribution of histological types of ovarian carcinomas according to current WHO criteria after central review of H&E-stained re-cuts from all available paraffin blocks is shown in Table 1 .
Both p16 INK4a and pRb immunostains of sufficient quality were available for further analysis from a total of 300 cases. Most cases were p16
INK4a -positive (283 out of 300; 94%), likewise a majority of cases showed some pRb immunoreactivity (292 out of 300; 97%), ISI and PPC for p16
INK4a and pRb, respectively, are given in Table 2 . Examples for staining results are given in Figure 1 . ISI and PPC were closely covariant (Po0.0001) for both markers. p16
INK4a and pRb expression levels were found to be independent from the established prognostic factors FIGO stage, postoperative residual tumour and age (Tables 3a and 3b) . A statistically significant, however weak, negative correlation between p16
INK4a and pRb PPC was observed (correlation coefficient PPC: À0.114, P ¼ 0.01; ISI: À0.091, P ¼ 0.08). Kaplan -Meier survival estimates showed a significantly worse prognosis for p16
INK4a -negative patients (Po0.001; Table 2, Figure 2A ). p16
INK4a -negative tumours were of no particular histological type. p16
INK4a staining results were independent from established prognostic markers (Table 3a) . Among p16
INK4a
-positive tumours (283 out of 300; 94%), survival Table 2 ). Furthermore, p16
INK4a expression levels were associated with Ki-S5 proliferation activity. Proliferation activity was higher in ovarian carcinomas with either negative or strong p16
INK4a expression, compared to cases with only weak or moderate expression levels (Figure 3) . Within the subgroups of p16
INK4a -negative and p16 INK4a -positive carcinomas, patients with low proliferation activity as measured by Ki-S5 immunostaining had a lower median survival as compared to those with a high proliferation (p16 INK4a negative, Ki-S5 low: 11.1 months, Ki-S5 high: 20.4 months; p16
INK4a positive, Ki-S5 low: 37.2 months, Ki-S5 high: 46.9 months) activity ( Figure 2B ). Immunohistochemical pRb expression analysis revealed an incremental deterioration of prognosis with increasing pRb ISI (P ¼ 0.004, Table 2, Figure 2C and D), as well as pRb PPC (P ¼ 0.001, Table 2 ). pRb protein expression levels were not associated with Ki-S5 proliferation activity (data not shown). The results of further univariate analyses of established clinical prognosticators are shown in Table 2 . Multivariate analysis including FIGO stage, postoperative residual tumour, ECOG performance status, age and Ki-S5 proliferation activity, established an independent prognostic significance of both pRb ISI (odds ratio: 2.98, P ¼ 0.002) and p16
INK4a expression (odds ratio 2.41, P ¼ 0.009 (Table 4) .
For the subgroup of nonoptimally debulked patients (P ¼ 0,015, Figure 2E ), as well as for the subgroup of optimally debulked patients (P ¼ 0.009, Table 2, Figure 2F ), pRb ISI was still found to be a significant prognosticator. Of note, no prognostic information could be derived from the established factors in the latter subgroup. In contrast to pRb ISI, pRb PPC (P ¼ 0.21) as well as INK4a expression and proliferative activity as measured by Ki-S5 immunohistochemistry. In our study, high pRb expression levels were shown to be significantly associated with a worse prognosis in the homogenous group of patients with advanced-stage ovarian cancers. Our findings confirm the results of a previous study suggesting a potential association of high pRb expression with decreased survival (Milde-Langosch et al, 2003) . In addition, our analysis suggested that low pRb expression levels may still be associated with a significantly superior survival in the subgroup of optimally debulked patients: five-year survival rates for patients with low pRb expression were 68.8%, compared to 46.1% survival rates in patients characterised by high pRb expression levels.
Of note, Dong et al. (1997b) found the prognosis to be worse in FIGO stage I tumours with low pRb expression. In that study, high expression levels of pRb were reported in advanced-stage carcinomas; however, no prognostic significance of pRb expression was reached for that subgroup. These findings further support the relevance of using uniform groups of patients characterised by defined sets of tumours, as well as consistent treatment regimens and follow-up schedules when analysing the potential value and clinical relevance of prognosticators of postoperative disease.
This study is limited by case numbers, especially in clinically important subgroups. Although thorough statistical analysis of the study population was performed, a selection bias cannot be completely ruled out.
Further evaluation using prospective study protocols will have to be performed to validate the results obtained in this retrospectively performed analysis. If confirmed, our findings may be of interest for clinical practice. Optimally debulked patients have a much better prognosis as compared to patients with residual tumour (du Bois et al, 2003) . However, a significant proportion of patients will relapse and finally die even in this favorable subgroup. Recently, complex gene expression profiles have been described as providing independent prognostic information in advanced stage ovarian cancer. Patients showing an unfavourable gene signature had a significantly worse prognosis. Although a similar trend was observed among optimally debulked patients, the prognostic impact did not reach statistical significance (Spentzos et al, , 2005 . Thus far it has not been possible to further subdivide completely debulked patients into prognostic subgroups. However, tools to identify different prognostic subgroups in this cohort might offer the opportunity for further clinical studies of aggressive maintenance therapy. The results of our study suggest that if the current findings are confirmed prospectively, the assessment of p16
Ink4a and pRb expression levels may prove to be a useful prognostic factor in advanced-stage ovarian carcinomas after standardised chemotherapy including completely debulked patients.
